Cargando…

Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma

INTRODUCTION: Immune checkpoint inhibitors (ICI) have been approved for patients with clear cell renal cell carcinoma (ccRCC), but not all patients benefit from ICI. One reason is the tumor microenvironment (TME) that has substantial influence on patient's prognosis and therapy response. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stenzel, Philipp J., Schindeldecker, Mario, Tagscherer, Katrin E., Foersch, Sebastian, Herpel, Esther, Hohenfellner, Markus, Hatiboglu, Gencay, Alt, Juergen, Thomas, Christian, Haferkamp, Axel, Roth, Wilfried, Macher-Goeppinger, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031108/ https://www.ncbi.nlm.nih.gov/pubmed/31881506 http://dx.doi.org/10.1016/j.tranon.2019.11.002

Ejemplares similares

Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma
por: Radspieler, Melissa Marie, et al.
Publicado: (2019)

Expression and Functional Characterization of the BNIP3 Protein in Renal Cell Carcinomas
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2017)

Prognostic relevance of androgen receptor expression in renal cell carcinomas
por: Foersch, Sebastian, et al.
Publicado: (2017)

Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma
por: Stenzel, Philipp J., et al.
Publicado: (2021)

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
por: Macher-Goeppinger, Stephan, et al.
Publicado: (2016)

Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2021)

MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen
por: Tagscherer, Katrin E., et al.
Publicado: (2016)

Senescence-Associated Molecules and Tumor-Immune-Interactions as Prognostic Biomarkers in Colorectal Cancer
por: Kellers, Franziska, et al.
Publicado: (2022)

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications()
por: Zhou, Xiaoguang, et al.
Publicado: (2015)

The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma
por: Weissinger, Daniel, et al.
Publicado: (2013)

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
por: Knoll, Maximilian, et al.
Publicado: (2015)

Hydronephrotic pelvic kidney mimicking urinary retention in an 18-year-old male
por: Reimold, Philipp, et al.
Publicado: (2022)

Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients
por: Wagener, N, et al.
Publicado: (2013)

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
por: Wagener, Nina, et al.
Publicado: (2010)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
por: Hoefflin, Rouven, et al.
Publicado: (2016)

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer
por: Thomas, Anita, et al.
Publicado: (2022)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Evolution of Salvage Radical Prostatectomy from Open to Robotic and Further to Retzius Sparing Surgery
por: Schuetz, Viktoria, et al.
Publicado: (2021)

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

Cavoatrial hypernephroma resection on cardiopulmonary bypass: Mild/normo-versus moderate hypothermia
por: Möbius, Andreas, et al.
Publicado: (2022)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Multimodal Deep Learning for Prognosis Prediction in Renal Cancer
por: Schulz, Stefan, et al.
Publicado: (2021)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
por: Luo, Bixian, et al.
Publicado: (2022)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1
por: Jacquot, Perrine, et al.
Publicado: (2023)

No association of CpG island methylator phenotype and colorectal cancer survival: population-based study
por: Jia, Min, et al.
Publicado: (2016)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy
por: Li, Heng, et al.
Publicado: (2019)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells
por: Nokhbehsaim, Marjan, et al.
Publicado: (2013)

As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner
por: Miao, Daojia, et al.
Publicado: (2022)

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based study
por: Alwers, Elizabeth, et al.
Publicado: (2020)

Response to neoadjuvant treatment among rectal cancer patients in a population-based cohort
por: Alwers, Elizabeth, et al.
Publicado: (2020)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bfqdbanqq1trs1bccvkjaj7lfl